CAS No. : 1001264-89-6

Product Details
For research use only. Not Intended for Therapeutic Use!
Cat No:I000069
Molecular Formula:C₂₄H₃₂ClN₅O₂
Molecular Weight:458.0
IC50:5 nM/18 nM/8 nM(Akt1/2/3) [1]
Price:Get quote
We would like to match the lowest price on market if possible.

Your information is safe with us.


Appearance:A crystalline solid
Cat No:I000069
Cas No:1001264-89-6

GDC-0068(RG 7440) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM, 620-fold selectivity over PKA.
IC50 value: 5 nM/18 nM/8 nM(Akt1/2/3) [1]
Target: Akt1/2/3
in vitro: Testing against a broad panel of 230 kinases, GDC-0068 only inhibits 3 kinases by >70% at 1 μM concentration (PRKG1α, PRKG1β, and p70S6K, with IC50 of 98 nM, 69 nM, and 860 nM, respectively). GDC-0068 displays >100-fold selectivity for Akt over PKA with IC50 of 3.1 μM. In LNCaP, PC3 and BT474M1 cells, GDC-0068 treatment inhibits the phosphorylation of the Akt substrate, PRAS40 with IC50 of 157 nM, 197 nM, and 208 nM, respectively. Furthermore, GDC-0068 selectively inhibits cell cycle progression and viability of cancer cell lines driven by Akt signaling, including those with defects in the tumor suppressor PTEN, oncogenic mutations in PIK3CA, and amplification of HER2, with strongest effects in HER2+ and Luminal subtypes.
in vivo: Oral administration of GDC-0068 in PC3 prostate tumor xenografts model induces down-regulation of p-PRAS40. In BT474-Tr xenografts, GDC-0068 treatment reduces pS6 and peIF4G levels, re-localizes FOXO3a to nucleus, and induces feedback upregulation of HER3 and pERK. Administration of GDC-0068 exhibits potent antitumor efficacy in multiple xenograft tumor models, including the PTEN-deficient prostate cancer models LNCaP and PC3, the PIK3CA H1047R mutant breast cancer model KPL-4, and MCF7-neo/HER2 tumor model.

[1]. Lin K. Abstract DDT02-01: GDC-0068: A novel, selective, ATP-competitive inhibitor of Akt. Cancer Res, 2011, 71(8 Supplement), abstract DDT02-01.
[2]. Tabernero J, et al. Ann Oncol, 2011, 22(suppl 3), abstract IL33.
[3]. Heidi M. Savage, et al. Abstract 966: Predictive biomarkers of the AKT inhibitor, GDC-0068, in single agent and combination studies. Cancer Res, 2012, 72(8 Supplement), 966.

Related Products
  • CAS No. :
    Product Name:

    GSK2110183 hydrochloride

    Cat No: I005868 View details
  • CAS No. :925681-41-0
    Product Name:

    Akt Inhibitor (10-NCP)

    Cat No: I010580 View details
  • CAS No. :58066-85-6
    Product Name:


    Cat No: A000585 View details
  • CAS No. :20784-50-3
    Product Name:


    Cat No: I002599 View details